News & Events
PRESS RELEASE

Scroll down

2023-05-04

HASTEN ACQUIRES COMMERCIAL RIGHTS IN CHINA FOR ROCHE’S ANTIBIOTIC ROCEPHIN®

- The acquisition will deliver strong commercial synergy with Hasten’s current critical care portfolio

 

Shanghai, May 4th , 2023 – Hasten Biopharmaceutic Co., Ltd (China) ("Hasten") today announced that it has acquired the commercial rights in China for Rocephin®, a long-acting, broad spectrum cephalosporin antibiotic, from Swiss multinational healthcare company, Roche.

 

Under the agreement, Hasten acquired Roche’s China mainland rights for Rocephin®, including the product’s Marketing Authorization, Intellectual Property, trademarks, and technology transfer. As a critical care product, Rocephin® is a broad-spectrum antibiotic with strong brand value for community acquired infections.

 

“Hasten is committed to building a leading innovative medical and healthcare enterprise in China. The acquisition of Rocephin® delivers strong commercial synergy with Hasten’s current critical care portfolio in the Emergency Room, Intensive Care Unit, and Surgery departments, and positions us well to continue providing best-in-class treatments to benefit more patients,” Summer Xia, CEO of Hasten Biopharma, said.

 

Hasten is an investment of CBC Group, Asia's largest healthcare-dedicated investment firm headquartered in Singapore, Hefei Industry Investment Group, and Feidong County of Hefei City.

 

公司地址:这里是公司地址后期需要替换设计占位后台可替换

企业邮箱:infu@singlera.com.cn

联系电话:+86-8888-8888

商务联系:BD@singlera.com.cn

人力资源:HR@singlera.com.cn